Skip to main content
Yili Chuanning Biotechnology Co., Ltd. logo

Yili Chuanning Biotechnology Co., Ltd. — Investor Relations & Filings

Ticker · 301301 ISIN · CNE100005WX0 LEI · 65560014DI6P8LN65I53 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 390 across all filing types
Latest filing 2026-03-30 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301301

About Yili Chuanning Biotechnology Co., Ltd.

https://www.klcnsw.com

Yili Chuanning Biotechnology Co., Ltd. specializes in the large-scale research, development, and production of antibiotic intermediates. The company operates extensive fermentation-based manufacturing facilities, positioning itself as a major global supplier of critical chemical precursors. Its primary product range includes erythromycin thiocyanate, 6-aminopenicillanic acid (6-APA), 7-aminocephalosporanic acid (7-ACA), and 7-aminodesacetoxycephalosporanic acid (7-ADCA). By integrating advanced synthetic biology and high-throughput screening technologies, the company optimizes biological fermentation processes to improve efficiency and product purity. A significant focus is placed on green manufacturing and the circular economy, employing sophisticated environmental treatment systems to manage industrial waste. These intermediates serve as essential building blocks for the synthesis of various antibiotic medications distributed to global markets.

Recent filings

Filing Released Lang Actions
伊犁川宁生物技术股份有限公司关于修订公司章程的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the revision of the company's articles of association (公司章程). It details changes to the company's business scope and board structure, including increasing the number of directors and committee compositions. The document states that these changes were approved by the board and will be submitted to the 2025 annual shareholders' meeting for approval. It also references the full revised articles of association being available on a public information website. The document is a formal announcement of governance changes and amendments to the company's charter, not the full governance report itself. It is not a full annual report, audit report, or financial report. It is not a proxy statement or voting results announcement. The content fits best under Governance Information (CGR) as it details internal rules, board structure, and governance practices changes.
2026-03-30 Chinese
伊犁川宁生物技术股份有限公司独立董事候选人声明与承诺（孙慧）
Board/Management Information Classification · 95% confidence The document is a formal declaration and commitment statement by an independent director candidate of a company. It details the candidate's qualifications, compliance with regulatory requirements, and commitments related to their role as an independent director. There are no financial statements, earnings data, or report summaries. The document is not an announcement of a report publication but a regulatory compliance and governance-related statement. This type of document fits best under Board/Management Information (MANG) as it relates to board member candidacy and governance disclosures.
2026-03-30 Chinese
伊犁川宁生物技术股份有限公司关于董事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of a new board of directors for the company 伊犁川宁生物技术股份有限公司. It details the nomination and qualifications of non-independent and independent director candidates, the process of cumulative voting at the upcoming 2025 annual shareholders meeting, and compliance with relevant laws and regulations. There is no financial data, audit information, or report content; rather, it is a formal disclosure about changes in the company's board composition. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2026-03-30 Chinese
长江证券承销保荐有限公司关于伊犁川宁生物技术股份有限公司及所属子公司开展外汇套期保值业务的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion from a securities underwriting and sponsorship company regarding the company's and its subsidiaries' engagement in foreign exchange hedging business. It includes purpose, business scope, risk analysis, risk control measures, accounting policies, and approval procedures. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a formal audit or review opinion related to the company's hedging activities, consistent with an Audit Report / Information (AR) filing type, which covers standalone audit reports and applied accounting principles. The document length is 3251 characters, which is relatively short but contains substantive content and detailed analysis, not just an announcement or certification. Therefore, the best classification is AR with high confidence.
2026-03-30 Chinese
伊犁川宁生物技术股份有限公司董事会审计委员会关于2025年会计师事务所履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm Tianjian Certified Public Accountants for the fiscal year 2025. It details the audit firm's qualifications, the process of reappointment, meetings held during the audit period, and an overall evaluation of the audit firm's performance. The document is not the audit report itself but a supervisory report on the audit firm's duties and performance. It is a standalone audit-related report focusing on the audit committee's oversight and the audit firm's execution, which fits the definition of an Audit Report / Information (AR). The document length is 1936 characters, which is short but contains substantive content about audit supervision, not merely an announcement or certification. Therefore, it should be classified as AR rather than RPA or RNS.
2026-03-30 Chinese
伊犁川宁生物技术股份有限公司关于续聘公司2026年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the company's audit firm for the fiscal year 2026. It details the qualifications, independence, and past performance of the audit firm, Tianjian CPA Firm, and the approval process by the board of directors. The document does not contain any financial statements or audit reports themselves but is an official notice about the audit firm appointment for the upcoming year. The document length is 3426 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report itself. However, since it is specifically about the appointment of the audit firm and not the audit report or results, it is best classified as an Audit Report / Information (AR) filing, which includes standalone audit-related announcements excluding full annual reports.
2026-03-30 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.